



Republic of Serbia
**COMMISSION FOR PROTECTION
OF COMPETITION**

25/IV Savska St., Belgrade
Number: 6/0-02-151/2018-9
Date: February 20, 2018

Published text contains protected data.
Protected data are presented with symbol [...] or in the range that the Commission finds to be an appropriate manner of protection.

Pursuant to Article 37(2) and Article 65(5) of the Law on Protection of Competition (Official Gazette of the RS 51/09 and 95/13), and Article 2(1/6) of the Tariff on the level of compensations for activities within the competence of the Commission for Protection of Competition (Official Gazette of the RS 49/11), deciding under the notification on concentration entered under number 6/0-02-151/2018-1 of January 19, 2018, submitted by company Laboratoire HRA-Pharma SAS, with registered seat at the address 15 Rue Béranger, 75003 Paris, France, registered in the Registry of the Paris Commercial Court under company number 420 796 582, via attorney at law Darija Ognjenović and others from the Law Firm of Prica i Partneri, 20 Kosančićev venac St., Belgrade, on February 20, 2018, President of the Commission for Protection of Competition enacts the following

DECISION

I Concentration of undertakings in summary procedure **IS APPROVED** created by acquisition of control on the part of company Laboratoire HRA-Pharma SAS, with registered seat at the address 15 Rue Béranger, 75003 Paris, France, registered in the Registry of the Paris Commercial Court under company number 420 796 582, over the global property rights to brand LYSODREN, implying the intellectual property rights and distribution and marketing rights of drugs, from company Bristol-Myers Squibb Company, registry number 0326501, with registered seat at the address 345 Park Avenue, New York, N.Y. 10154, USA, created pursuant to the Asset purchase agreement.

II IT IS ESTABLISHED that the Party, Laboratoire HRA-Pharma SAS, with registered seat at the address 15 Rue Béranger, 75003 Paris, France, via attorneys at law from the Law Firm of Prica i Partneri, executed payment in the amount of RSD 2,962,500.00 (in words: two million, nine hundred sixty-two thousand, five hundred dinars) on January 22, 2018 to the account of the Commission for Protection of Competition, which represents stipulated amount of the fee as compensation for issuing decision on approval of concentration in summary procedure.